DEPEA | 119486-07-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: DEPEA
• 英文别名: Ethyl(1-phenylbutan-2-yl)amine；N-ethyl-1-phenylbutan-2-amine
• CAS: 119486-07-6
• 化学式: C₁₂H₁₉N
• mdl: MFCD12154200
• 分子量: 177.29
• InChiKey: KHWYSUBVXWWBRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  DEPEA 在 lithium aluminium tetrahydride 作用下， 以 乙醚 、 苯 为溶剂， 生成 3,4,5-Trimethoxy-benzoesaeure-<4-(N-ethyl-N-(1-ethyl-phenethyl))>-amino-butylester
  参考文献：
  名称：

  Kralt,T. et al., Recueil des Travaux Chimiques des Pays-Bas, 1961, vol. 80, p. 330 - 357

  摘要：

  DOI：
• 作为产物：
  描述：

  2-Acetamino-1-phenyl-butan 在 lithium aluminium tetrahydride 作用下， 以 乙醚 为溶剂， 生成 DEPEA
  参考文献：
  名称：

  一些1-苄基环丙胺的合成和厌食活性。

  摘要：

  DOI：

  10.1021/jm00299a007
• 作为试剂：
  描述：

  3-(2,3-二氢-5-苯并呋喃)-丙酸 、 9b-amino-4b-hydroxy-7-isopropyl-4b,9b-dihydro-5-oxa-indeno[2,1-a]inden-10-one 在 DEPEA 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.17h， 以24%的产率得到N1-(4b-hydroxy-7-isopropyl-10-oxo-4b,10-dihydro-9bH-indeno[1,2-b]benzofuran-9b-yl)-N2-methyloxalamide
  参考文献：
  名称：

  NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT

  摘要：

  公开号：

  EP2933254B1

文献信息

• NOVEL COMPOUND, PHARMACEUTICALLY ACCEPTABLE SALT OR OPTICAL ISOMER THEREOF, METHOD FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF VIRAL DISEASES CONTAINING SAME AS ACTIVE INGREDIENT
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：US20150336920A1

  公开（公告）日：2015-11-26

  The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis A, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media.

  本发明涉及一种新型化合物，一种药学上可接受的盐或其光学异构体，一种制备方法，以及一种包含其作为活性成分的用于预防或治疗病毒性疾病的制药组合物。本发明的新型化合物不仅细胞毒性低，而且对柯萨奇病毒、肠道病毒、回肠病毒、脊髓灰质炎病毒和鼻病毒等小RNA病毒具有出色的抗病毒活性，因此可以有效地用作预防或治疗儿童麻痹症、急性出血性结膜炎、病毒性脑膜炎、手足口病、水痘、甲型肝炎、肌炎、心肌炎、胰腺炎、糖尿病、流行性肌痛、脑炎、感冒、疱疹咽峡炎、口蹄疫、哮喘、慢性阻塞性肺病、肺炎、鼻窦炎或中耳炎的制药组合物。
• HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE
  申请人：Thermolife International, LLC

  公开号：EP3938341A1

  公开（公告）日：2022-01-19
• Hexylamine Salts and Methods of Using Hexylamine
  申请人：ThermoLife International, LLC

  公开号：US20200405662A1

  公开（公告）日：2020-12-31

  Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprising hexyalmine, for example, for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and/or memory in a human subject.
• [EN] HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE<br/>[FR] SELS D'HEXYLAMINE ET PROCÉDÉS D'UTILISATION D'HEXYLAMINE
  申请人：THERMOLIFE INT LLC

  公开号：WO2020214841A1

  公开（公告）日：2020-10-22

  Salts of hexylamine, for example, hexylamine succinate and tri-hexylamine citrate and their method of production are described. The disclosure also relates to compositions comprises hexyalmine and the use of hexylamine for for reducing appetite in a human subject, treating obesity in a human subject, preventing obesity in a human subject, preventing weight gain in a human subject, increasing fat loss in a human subject, treating an overweight human subject, increasing athletic performance in a human subject, increasing endurance in a human subject, increasing muscle strength in a human subject, improving cognitive function in a human subject, treating ADHD in a human subject, increasing sweating in a human subject, reducing reaction time of a human subject, increasing psychomotor vigilance of a human subject, enhancing memory in a human subject, increasing central nervous system activity in a human subject, and enhancing alertness, attention, concentration, and/or memory in a human subject.
• Kralt,T. et al., Recueil des Travaux Chimiques des Pays-Bas, 1961, vol. 80, p. 330 - 357
  作者：Kralt,T. et al.

  DOI：——

  日期：——